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Abstract 
Immobilized Artificial Membrane (IAM) chromatography columns have been used to model the in vivo 
distribution of drug discovery compounds. Regis Technologies Inc., the manufacturer, had to replace the 
silica support and consequently introduced a new IAM.PC.DD2 column that shows slightly different 
selectivity towards acidic and basic compounds. The application of the new IAM.PC.DD2 columns has been 
evaluated and the in vivo distribution models have been compared with the previous batches of columns. It 
was found that due to the improved endcapping of the silica, some of the positively charged drug 
molecules showed shorter retention than previously published. Therefore, the column system suitability 
data have been updated. However, these differences do not significantly affect the previously published 
models for the volume of distribution, brain tissue binding and drug efficiency. Therefore, the published 
models can be used with the new IAM.PC.DD2 columns. 
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Introduction 
Pidgeon and Venkataran [1] patented a method for immobilizing phospholipids on HPLC-grade silica 
stationary phases. The immobilized phospholipids mimic the lipid environment of a fluid cell membrane on 
a solid matrix. The retention factors (k) of compounds obtained on the IAM stationary phase are 
proportional to their affinity (partition coefficient) (K) to phospholipids according to the equation (1): 
log k(IAM) = log K(IAM) + log (Vs/Vm)                                  (1) 
where k is the retention factor obtained from the retention time (tR) and the dead time (t0) according to 
equation (2) 
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k = (tR-t0)/t0  (2) 
and Vs/Vm is the volume ratio of the stationary and mobile phases, respectively. Many drug molecules bind 
strongly to phospholipids as it is a pre-requisite for membrane permeability. To reduce the retention times 
various concentrations of acetonitrile can be used in the mobile phase. There is a linear relationship 
between the log k values and the percentage of acetonitrile in the mobile phase that allows the 
extrapolation of the retention factor to the zero percentage of acetonitrile, i.e. to the pure aqueous buffer 
(log k0) as shown by equation 3. 
log k = slope ∙ ACN% + log k0 (3) 
Equation 3 enables the calculation of the acetonitrile concentration that is necessary to achieve  
log k = 0, when the retention time is exactly double that of the dead time, which means an equal 
distribution of the compound in the mobile and the IAM stationary phase [2]. This acetonitrile 
concentration expressed in volume percentage is called the Chromatographic Hydrophobicity Index (CHI 
(IAM)) [3]. It has also been shown that the CHI (IAM) values have linear relationships with the gradient 
retention times of the compounds obtained on the IAM stationary phases. By using an acetonitrile gradient 
of 0 % to a maximum of 85 % the obtained gradient retention times can be calibrated from the CHI (IAM) 
values by using a set of standards, eliminating the need to carry out isocratic measurements. The so 
obtained CHI (IAM) values show a good correlation to the log k0 (IAM) values, that are the extrapolated 
logarithmic retention factors to 0 % acetonitrile concentration in the isocratic mode. The chromatographic 
determination of phospholipid-binding is based on measuring gradient retention times. It is independent of 
the amount of compound injected onto the column, so there is no need for quantitative analysis. The time 
measurement is very reproducible, and the calibrated (relative) gradient retention data are suitable for 
inter-laboratory comparison and application in published models of in vivo drug distribution. The data so 
obtained can be compiled in databases and is suitable for use in establishing quantitative structure- 
retention relationships, thus enabling chemists to design compounds with the appropriate IAM binding. 
The application of IAM chromatography as an aid in drug discovery has been reviewed extensively in 
recent years [4-8]. The molecular factors that influence IAM retention have also been discussed [9,10]. It 
has been found that IAM columns retain strongly positively charged compounds as the IAM columns are 
negatively charged on the surface similar to cell membranes [11-13]. Several applications of IAM 
chromatography have also published [14] and this is summarized below. 
Intestinal absorption and drug distribution depend on a compound’s partitioning into phospholipids. 
Compounds have to possess a certain degree of affinity to membranes in order to permeate through the 
biological phospholipid bilayers. Therefore, IAM chromatography can provide an insight into the potential 
intestinal absorption of compounds [15]. As tissues represent a more non-polar lipid environment relative 
to the plasma, the human volume of distribution can be modelled by the binding differences between IAM 
and human serum albumin (HSA) [13,16], as shown by equation (4):   
log Vdss= 0.44 log K (IAM) – 0.22 log K (HSA) – 0.66 (4) 
The sum of the albumin and phospholipid-binding inversely correlates to the unbound fraction of the 
compounds in tissues according to equation (5)  [17].  
log fut = -0.66 log K (HSA) – 0.52 log K (IAM) + 0.55 (5) 
The in vivo drug efficiency can be modelled by the sum of the IAM and HSA binding of compounds [18] 
according to equation 6.  The in vitro DRUGeff shows an excellent correlation with the in vivo DRUGeff. Drug 
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efficiency and potency enables early dose estimation as drug efficiency approximates to the proportion of 
free drug concentration and dose [19]. 
log DRUGeff= 2 - (0.23 log K (HSA) + 0.43 log K (IAM) - 0.72) (6) 





and also show promiscuous binding, interacting with several targets, 
causing potential toxicity and side effects  [21]. 
At present Regis Technologies Inc. (Morton Grove, IL, USA) is the only manufacturer of the Immobilized 
Artificial Membrane (IAM) stationary phase. The stationary phase contains only a monolayer of the 
phosphatidylcholine (PC) with the aliphatic part chemically bonded to the silica while the choline polar 
head group faces towards the mobile phase. Initially, “Type A” silica was used in the bonding procedure. 
The PC molecule has only one alkyl chain available with the second alkyl chain directly bonded to the silica 
surface. In this way, a denser bonding could be achieved which was closer to the natural density of PC 
molecules on the cell surface. However, in 2018 the company had to change the base silica material to a 
newer “Type B” as the old supply was no longer available. “Type B” silica has been chosen as the closest in 
properties to “Type A” regarding the specific surface area, pore size and particle size. When testing the 
retention selectivity of the new IAM.PC.DD2 columns which were otherwise manufactured in the same 
way, differences were observed towards acidic and basic molecules. This was somewhat surprising as the 
new silica support had identical physical specifications to the previously used silica (10 µm particle size, 
300 Å pore size and nearly identical surface area).  However, given the newer silica is of a much higher 
purity with only single ppm metal content, these observations are understandable as the new silica 
provides a much more inert surface and likely contributes to less non-specific binding interactions.  
The difference in selectivity can also be attributed to the different arrangements of the positive and 
negative charges of the choline headgroup on the stationary phase surface, again somewhat affected by 
the higher purity silica during the bonding process.  The new batches of columns did not pass the original 
system suitability test criteria. Hence the aim was to establish new CHI (IAM) values for the system 
suitability test compounds that could be reproduced on the new batches of IAM columns. In this paper, the 
investigation of the selectivity difference is reported using over 70 marketed drug molecules and the in 
vivo distribution models are compared for the old and the new batches of IAM.PC.DD2 stationary phases. 
The estimated volume of distribution data was compared with the data from the previously published 
models. The differences of the models for the estimated brain tissue binding and drug efficiency values of 
the known drug molecules are investigated and compared with the published data obtained using the 
previous batches of IAM.PC.DD2 columns. 
Experimental  
All high-performance liquid chromatography measurements were performed on an Agilent 1100 Series 
HPLC instrument equipped with an ultraviolet diode array detector (DAD). 
Measurements of membrane binding using immobilized artificial membrane (IAM) chromatography 
The IAM binding was measured using IAM.PC.DD2 HPLC columns (Regis Technologies, Inc., IL, USA) with 
dimensions of 100 x 4.6 mm, particle size 10 µm with 300 Å pore size.  
Two batches of IAM.PC.DD2 columns were studied (R20511-014-3 and P20511-014-3) that had been 
prepared using the new batches of silica support. The selectivity and the models obtained were compared 
with the published average IAM data obtained on the columns manufactured between 2004 and 2012 [14]. 
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Mobile phase A was 50 mM ammonium acetate adjusted to pH 7.4 and mobile phase B was 100 % 
acetonitrile. The mobile phase flow rate was 1.5 mL/min and the run time was 6 min. The acetonitrile 
gradient was applied from 0 to 85 % from 0 to 4.75 min and kept at 85 % until 5.15 min. From 5.15 to 
5.25 min the acetonitrile concentration dropped back to 0 %. 
The retention times were standardized using the IAM calibration mixture, containing octanophenone, 
heptanophenone, hexanophenone, valerophenone, butyrophenone, propiophenone, acetophenone, 
acetanilide and paracetamol.  The retention times of the compounds were plotted against the isocratically 
determined and predefined CHI (IAM) values [4] listed in Table 1. The slope and intercept of the obtained 
straight line was used to calculate the CHI IAM values of new compounds. The CHI IAM values were 
converted to the octanol/water lipophilicity scale and expressed as log K (IAM) values using equation (7). 
log K (IAM) = 0.29 exp(0.026 CHI (IAM) + 0.70 (7) 
The so-obtained log KIAM values express the membrane partition comparable to the octanol/water 
lipophilicity as described in reference [22]. A typical chromatogram is shown in Figure 1. 
 
Figure 1. A typical chromatogram obtained on IAM.PC.DD2 100 x 4.6 mm HPLC column. Flow rate: 1.5 mL/min; 
Mobile phase A: 50 mM ammonium acetate adjusted to pH 7.4, mobile phaseB: acetonitrile. Run time 6 min; 
Gradient: 0 to 4.75 min 0 to 85 % B, 4.75 to 5.15 min 85 % B, 5.15 to 5.25 min 0 % B; Detection wavelength: 250 nm 
The natural state of the phosphatidylcholine headgroup on the IAM stationary phase provides the 
column selectivity that was tested using the system suitability test compounds containing acidic, basic and 
neutral compounds. 
Protein binding measurements using biomimetic protein stationary phases  
The interaction of the compounds listed in Table 2 with human serum albumin (HSA) has been 
measured using commercially available chemically bonded HSA columns (Chiralpak-HSA from HiChrom, UK) 
with the dimensions of 50 x 3 mm and a particle size of 5 μM. 
Mobile phase A was 50 mM ammonium acetate adjusted to pH 7.4 and mobile phase B was 2-propanol. 
The flow rate was 1.5 mL/min and the run time was 6 min. The 2-propanol gradient was applied from 0 to 
35 % from 0 to 3.00 min and kept at 35 % until 4.00 min. From 4.00 to 4.25 min the 2-propanol 
concentration was dropped back to 0 %. Although column manufacturers suggest using pH 7 for chiral 
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separations using the HSA column, in this case, the pH 7.4 mobile phase is used to mimic the plasma pH for 
the plasma protein binding measurements. 
Table 1. The constant CHI (IAM) and log K (IAM) values for the 
calibration set of compounds with typical retention times. 
The retention times were standardized 
using the calibration set of compounds 
described previously [23]. 
Compounds studied 
In this study, 72 commercial drugs from 
diverse therapeutic areas have been 
analysed. 50 µl of 10 mM DMSO solutions of 
the drugs were diluted down to 150 µl and 10 
µl of the diluted solution was injected onto the HPLC columns. The clinical volume of distribution data for 
all of the drugs is available in the literature [13].  
Table 2 shows the marketed drug molecules and their clinical volume of distribution data obtained from 
reference [13]  and the previously measured CHI (IAM) data [14] using an IAM column manufactured by 
Regis Technologies between 2004 and 2012. 
Data analysis 
The statistical analysis was performed using JMP 13 (SAS Institute, USA). 
Results and Discussion 
The selectivity and reproducibility of IAM.PC.DD2 columns have been extensively studied. First, the CHI 
(IAM) values of the system suitability test compounds (see Table 2) were scrutinized. The CHI (IAM) values 
of the test compounds were then compared with the CHI (IAM) values obtained on the new batches of 
IAM.PC.DD2 columns. It was found, as shown in Table 3, that carbamazepine, warfarin, indomethacin, 
nicardipine, ketoprofen, haloperidol and budesonide had very similar CHI (IAM) values. However, 
imipramine and chlorpromazine showed greater than the 5 CHI (IAM) unit deviations which would be 
within the experimental error and therefore they did not pass the system suitability criteria. These 
compounds are strong bases and positively charged at pH 7.4. Most probably the new IAM.PC.DD2 
columns have less negative charge on the surface and therefore reduce the retention times of positively 
charged compounds. It is also possible that more of the free silanol groups were end-capped which would 
contribute to a shorter retention of basic compounds. Therefore, the system suitability criteria were 
changed for basic compounds. The “new” CHI (IAM) values are listed in Table 3. 
The in vivo distribution models were re-examined using the data from the new IAM.PC.DD2 columns. 
Because of the selectivity differences, it was essential to investigate the CHI (IAM) values for a larger set of 
compounds and check how the previously described in vivo distribution models performed using the data 
from the new columns manufactured with the new silica material. 
The 72 drug molecules from the original set of marketed drugs for which the models were developed 
[13] were analysed on the new IAM.PC.DD2 columns and the HSA column. Table 4 shows the CHI (IAM) 
values and the log k HSA binding data obtained from reference [13] and remeasured in this study. 
Compound CHI (IAM) log K (IAM)  tR 7.4 (min) 
Octanophenone 49.4 4.97 4.37 
Heptanophenone 45.7 4.30 4.17 
Hexanophenone 41.8 3.71 3.93 
Valerophenone 37.3 3.16 3.66 
Butyrophenone 32.0 2.62 3.32 
Propiophenone 25.9 2.15 2.90 
Acetophenone 17.2 1.67 2.34 
Acetanilide 11.5 1.45 2.04 
Paracetamol 2.90 1.20 1.58 
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Table 2. The name of the marketed drugs, their CAS number, their previously published CHI (IAM) data and 
the logarithm of their clinical volume of distribution.  
Compound CAS NO Acid/base character 
CHI (IAM) 
[14] 
log Vdss [13] 
Acecainide 32795-44-1 basic 23.3 0.10 
Acetanilide 103-84-4 neutral 10.7 -0.13 
Acetazolamide 59-66-5 neutral 1.7 -0.46 
Alclofenac 22131-79-9 acidic 17.8 -1.10 
Amoxapine 14028-44-5 basic 56.5 1.67 
Bamethan 3703-79-5 basic 18.6 0.01 
Betamethasone 378-44-9 neutral 31.7 0.18 
Carbamazepine 298-46-4 neutral 26.5 -0.09 
Chlorpromazine 50-53-3 basic 61.9 2.15 
Cinoxacin 28657-80-9 acidic 1.6 -0.42 
Colchicine 64-86-8 neutral 23.7 0.03 
Cytarabine 147-94-4 weak base -15.0 -0.31 
Diazoxide 364-98-7 weak acid 24.7 -0.16 
Diclofenac 15307-86-5 acidic 33.5 -0.67 
Diprophylline 479-18-5 neutral -4.0 -0.24 
Ethinyl estradiol 57-63-6 neutral 46.8 0.39 
Famotidine 76824-35-6 weak base 15.7 -0.06 
Felbamate 25451-15-4 neutral 19.1 -0.64 
Felodipine 72509-76-3 neutral 46.1 0.35 
Fenoprofen 31879-05-7 acidic 17.2 -1.27 
Finasteride 98319-26-7 neutral 38.9 0.30 
Floxacillin 5250-39-5 acidic 23.4 -0.56 
Flumazenil 78755-81-4 neutral 18.4 -0.04 
Flurbiprofen 5104-49-4 acidic 26.8 -1.56 
Furosemide 54-31-9 acidic 21.4 -0.71 
Gemfibrozil 25812-30-0 acidic 32.9 -1.34 
Glipizide 29094-61-9 acidic 21.1 -0.73 
Griseofulvin 126-07-8 neutral 33.1 0.12 
Hydrochlorothiazide 58-93-5 weak acid 15.9 -0.13 
Hydrocortisone 50-23-7 neutral 27.9 0.12 
Imipramine 50-49-7 basic 51.6 1.16 
Indomethacin 53-86-1 acidic 25.3 -0.96 
Isradipine 75695-93-1 neutral 40.0 0.13 
Ketoconazole 65277-42-1 weak base 42.9 0.32 
Ketoprofen 22071-15-4 acidic 21.9 -1.01 
Labetalol 36894-69-6 amphoteric 43.9 0.71 
Lignocaine 137-58-6 basic 32.6 0.40 
Methylprednisolone 83-43-2 neutral 32.1 0.16 
Metronidazole 443-48-1 weak base -3.3 -0.25 
Minoxidil 38304-91-5 weak base 19.0 -0.04 
Nabumetone 42924-53-8 neutral 38.4 0.03 
Nadolol 42200-33-9 basic 20.2 -0.33 
Nicardipine 55985-32-5 weak base 45.9 0.47 
Nifedipine 21829-25-4 neutral 29.0 -0.04 
Nitrendipine 39562-70-4 neutral 40.5 0.16 
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Papaverine 58-74-2 weak base 34.4 0.00 
Pentoxifylline 6493-05-6. neutral 12.0 -0.10 
Perphenazine 58-39-9 basic 56.3 1.35 
Phenytoin 57-41-0 weak acid 31.6 0.03 
Pindolol 13523-86-9 basic 42.0 0.85 
Prazosin 19216-56-9 weak base 31.6 -0.05 
Prednisolone 50-24-8 neutral 28.0 0.14 
Prednisone 53-03-2 neutral 25.9 0.05 
Primidone 125-33-7 neutral 8.9 -0.15 
Probenecid 57-66-9 acidic 20.1 -0.75 
Procainamide 614-39-1 basic 19.9 0.02 
Propanolol 525-66-6 basic 50.8 1.29 
Propylthiouracil 51-52-5 weak acid 3.9 -0.34 
Proxyphylline 603-00-9 neutral 1.1 -0.85 
Sulfachlorpyridazine 80-32-0 acidic 6.0 -0.76 
Sulfameter 651-06-9 acidic 3.7 -0.61 
Sulfamethoxypyridazine 80-35-3 weak acid 9.6 -0.59 
Sulfinpyrazone 57-96-5 acidic 26.1 -0.65 
Sulfisoxazole 127-69-5 acidic 2.9 -0.72 
Sulphadimidine 57-68-1 amphoteric 34.6 0.22 
Sulpiride 15676-16-1 basic 25.5 0.12 
Tamoxifen 10540-29-1 basic 58.7 1.48 
Theobromine 83-67-0 weak acid -4.1 -0.25 
Tolfenamic Acid 13710-19-5 acidic 36.6 -0.76 
Trazodone 19794-93-5 weak base 36.3 0.01 
Trimethoprim 738-70-5 weak base 20.8 -0.06 
Warfarin 81-81-2 acidic 19.9 -0.78 
Table 3. The CHI (IAM) obtained from the literature [13] (CHI (IAM) reference), the 
CHI (IAM) values obtained on the new IAM.PC.DD2 columns and the acid/base 
character of the IAM calibration compounds  
Compound Acid/base character CHI (IAM)     CHI (IAM) “new” 
Carbamazepine neutral 28.9 27.0 
Colchicine neutral 23.7 23.0 
Warfarin acidic 19.9 24.0 
Indomethacin acidic 32.5 30.0 
Nicardipine weak base 45.9 45.0 
Propranolol basic 45.1 42.0 
Imipramine basic 54.1 45.0 
Ketoprofen strong acid 21.9 20.0 
Chlorpromazine basic 61.9 54.0 
Haloperidol basic 44.3 48 
Budesonide neutral 38.7 38 
 
Figure 2 shows the plot of the experimental CHI (IAM) values on IAM.PC.DD2 columns P20511-014-3 
and R2055-014-3. The CHI (IAM) values obtained on the columns are very similar indicating good batch to 
batch reproducibility of the new columns.  
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Table 4. The experimental CHI (IAM) values of the investigated compounds obtained on the new IAM.PC.DD2 










log K HSA 
from ref [13] 
log K HSA 
Acecainide 23.30 17.72 17.57 0.69 0.52 
Acetanilide 10.70 11.55 11.50 0.62 0.43 
Acetazolamide 1.66 0.99 0.74 1.47 1.44 
Alclofenac 17.80 20.47 21.63 5.11 5.40 
Amoxapine 56.50 45.41 44.74 2.15 2.70 
Bamethan 18.60 18.53 18.03 0.49 0.42 
Betamethasone 31.70 30.18 30.05 1.09 1.39 
Carbamazepine 26.50 27.18 27.07 1.99 1.81 
Chlorpromazine 61.90 51.54 50.94 1.18 1.27 
Cinoxacin 1.60 5.31 6.67 0.79 0.91 
Colchicine 23.70 23.45 23.18 0.69 0.24 
Cytarabine -15.00 -6.76 -6.99 1.59 1.87 
Diazoxide 24.70 23.39 23.44 5.42 5.58 
Diclofenac 33.50 35.18 35.85 0.63 0.24 
Diprophylline -4.00 -1.49 -1.98 4.1 4.24 
Ethinyl Estradiol 46.80 45.30 45.23 0.46 0.50 
Famotidine 15.70 16.82 16.08 1.39 3.43 
Felbamate 19.07 39.16 39.21 3.46 4.15 
Felodipine 46.10 44.37 44.45 5.91 6.11 
Fenoprofen 17.20 27.17 28.26 1.58 2.32 
Finasteride 38.90 37.15 37.17 3.62 3.55 
Floxacillin 23.40 23.76 24.59 0.56 0.65 
Flumazenil 18.40 18.27 18.27 7.81 8.50 
Flurbiprofen 26.80 30.23 30.89 1.26 4.01 
Furosemide 21.41 21.96 22.69 3.64 8.50 
Gemfibrozil 32.90 33.70 34.53 3.32 4.05 
Glipizide 21.10 22.82 23.22 1.49 1.92 
Griseofulvin 33.10 31.06 30.98 0.77 0.80 
Hydrochlorothiazide 15.90 13.04 13.08 0.92 1.05 
Hydrocortisone 27.90 27.23 27.02 1.95 2.59 
Imipramine 51.60 45.58 44.81 6.17 5.59 
Indomethacin 25.30 32.49 33.16 2.86 3.36 
Isradipine 40.00 39.11 39.16 2.9 3.30 
Ketoconazole 42.90 39.50 39.26 4.8 5.40 
Ketoprofen 21.90 22.93 23.89 1.28 1.80 
Labetalol 43.90 38.29 37.48 0.69 0.52 
Lignocaine 32.60 24.89 25.53 1.35 1.53 
Methylprednisolone 32.10 30.91 30.77 0.76 0.28 
Metronidazole -3.30 -2.71 -3.24 0.66 0.72 
Minoxidil 19.00 15.93 16.08 3.16 3.41 
Nabumetone 38.40 35.90 35.96 0.49 2.14 
Nadolol 20.20 19.89 19.23 2.93 3.55 
Nicardipine 45.90 43.82 43.73 1.41 1.95 
Nifedipine 29.00 28.11 28.16 3.13 3.37 
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Nitrendipine 40.50 39.06 39.19 2.35 2.70 
Papaverine 34.40 31.22 31.15 0.63 0.39 
Pentoxifylline 12.00 14.04 13.87 3.27 4.03 
Perphenazine 56.30 49.57 48.97 1.6 2.02 
Phenytoin 31.60 30.18 30.20 0.54 0.63 
Pindolol 42.00 25.69 25.31 1.81 2.40 
Prazosin 31.60 29.82 29.35 0.89 0.95 
Prednisolone 28.00 27.31 27.20 0.8 1.08 
Prednisone 25.90 25.25 25.13 0.62 0.42 
Primidone 8.90 10.31 10.49 3.44 4.01 
Probenecid 20.10 23.45 24.38 0.76 0.49 
Procainamide 19.90 11.73 11.89 0.73 1.67 
Propranolol 50.80 42.24 41.46 0.63 1.02 
Propylthiouracil 3.90 6.56 6.52 2.67 3.21 
Proxyphylline 1.10 10.05 10.89 1.97 3.02 
Sulfachlorpyridazine 6.00 10.08 10.83 2.04 2.20 
Sulfameter 3.70 6.92 7.09 4.09 2.44 
Sulfamethoxypyridazine 9.60 11.11 11.16 2.33 4.27 
Sulfinpyrazone 26.10 26.19 26.89 3.17 2.66 
Sulfisoxazole 2.90 6.48 7.37 1.54 3.68 
Sulphadimidine 34.55 10.89 11.09 0.75 1.72 
Sulpiride 25.50 15.80 16.15 4.84 0.71 
Tamoxifen 58.70 54.23 53.78 1.29 4.82 
Theobromine -4.10 -3.16 -3.71 4.68 0.27 
Tolfenamic Acid 36.60 40.72 41.53 2.46 6.60 
Trazodone 36.30 34.09 33.86 0.8 3.06 
Trimethoprim 20.80 20.99 20.52 4.45 0.95 
Warfarin 19.90 23.47 24.18 0.7 4.16 
Figure 3 shows the plot of the CHI (IAM) from the literature [13], reference CHI (IAM), with the 
experimental CHI (IAM) values using the IAM.PC.DD2 column R2055-014-3. The CHI (IAM) values of 
procainamide, sulpiride, zolmitriptan and pindolol were outliers from the correlation with lower CHI (IAM) 
values on the new batches of IAM columns. Compounds are considered outliers when the difference 
between the measured and predicted value is greater than the double of the standard error of the 
estimate, in this case 7.2 CHI IAM units. The slope of the regression line (red) is less than one (0.81) and the 
regression line is different from the line of unity (green). When these 4 strong basic compounds are left out 
from the correlation, the correlation coefficient increases to 0.96 and the slope increases to 0.82 as shown 
in Figure 4. 
The results shown in Figure 4 suggests that the rank order of the phospholipid binding will be very 
similar using the CHI IAM data obtained on the new IAM.PC.DD2 column and the old IAM.PC.DD2 column. 
However, some basic compounds may show significantly weaker phospholipid binding. The absolute CHI 
IAM values maybe lower when the new batches of IAM columns are used. 
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Figure 2. The plot of the experimental CHI (IAM) values on IAM.PC.DD2 columns P20511-014-3 and R20511-014-3 
 
Figure 3. The plot of the CHI (IAM) values from the literature [13] (reference CHI (IAM)) with the CHI (IAM) 
values using IAM.PC.DD2 column R25011-014-3. The green line is the line of unity. 
 
Figure 4. Comparison of the experimental CHI (IAM) values obtained on the IAM.PC.DD2  (R20511-014-3) column 
with the reference CHI (IAM) values without the 4 strong basic compounds. The green line is the line of unity 
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The human clinical volume of distribution and protein binding data of the investigated marketed drugs 
The volume of distribution model is based on two properties of the compounds, the IAM binding and 
the human serum albumin (HSA) binding.  Therefore, the IAM binding data obtained using the new 
IAM.PC.DD2 columns were examined in the models of the human clinical volume of distribution together 
with the re-measured protein binding data. 
Figure 5 shows the reproducibility of the HSA columns by plotting the newly measured log K (HSA) 
values as a function of the “reference log K (HSA) “ values published previously [13]. It can be seen that the 
slope is very close to 1 and the intercept is very close to 0. There are slightly greater discrepancies between 
the reference and the re-measured log K (HSA) values for strongly bound compounds. This shows that the 
specific binding sites of the human serum albumin may vary only slightly from column to column. With this 
excellent agreement between the log K (HSA) values obtained on various Chiral HSA columns, it can be 
assumed that they would not affect the volume of distribution model which is based on two binding 
properties for the compounds, namely the IAM and HSA binding. 
 
Figure 5 The plot of the log K (HSA) values from the literature [13] and the re-measured log K (HSA) for this 
study 
Estimating the volume of distribution using the old and new IAM.PC.DD2 columns 
The logarithmic values of the HSA and IAM binding data have been used to estimate the human clinical 
volume of distribution. Using the published equation (equation 4), the estimated values are compared 
using the IAM data obtained on columns R20511-014-3 and P20511-014-3 and the IAM data from the 
literature [12]. 
The estimated log Vdss values have been calculated using equation 4 and the measured log K (HSA) and 
log K (HSA) data obtained on the new IAM.PC.DD2 columns. The estimated log Vdss values are listed in 
Table 5 together with the acid/base character of the compounds. 
Figure 6 shows the plot of the estimated log Vdss values using the CHI (IAM) values obtained on the 
IAM.PC.DD2 column P20511-014-3 and those derived from the reference CHI (IAM) values. A good 
correlation was found between the estimated log Vdss values. In this study equation 4 was used with the 
same log K (HSA) values and different log K (IAM) values (depending on which IAM column was used). 
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Table 5. The estimated log Vdss values of the investigated compounds using equation 4 and their acid/base 
character 







Acecainide basic -0.03 -0.03 0.1 
Acetanilide neutral -0.12 -0.12 -0.13 
Acetazolamide neutral -0.47 -0.47 -0.46 
Alclofenac acidic -1.04 -1.02 -1.1 
Amoxapine basic 0.62 0.57 1.67 
Bamethan basic 0.01 0 0.01 
Betamethasone neutral 0.12 0.12 0.18 
Carbamazepine neutral -0.07 -0.07 -0.09 
Chlorpromazine basic 0.88 0.82 2.15 
Cinoxacin acidic -0.38 -0.37 -0.42 
Colchicine neutral 0.02 0.01 0.03 
Cytarabine weak base -0.26 -0.26 -0.31 
Diazoxide weak acid -0.19 -0.19 -0.16 
Diclofenac acidic -0.6 -0.57 -0.67 
Diprophylline neutral -0.22 -0.23 -0.24 
Ethinyl estradiol neutral 0.28 0.27 0.39 
Famotidine weak base -0.04 -0.05 -0.06 
Felbamate neutral 0.07 0.07 -0.64 
Felodipine neutral 0.23 0.23 0.35 
Fenoprofen acidic -1.02 -0.98 -1.27 
Finasteride neutral 0.21 0.21 0.3 
Floxacillin acidic -0.55 -0.53 -0.56 
Flumazenil neutral -0.04 -0.04 -0.04 
Flurbiprofen acidic -1.44 -1.42 -1.56 
Furosemide acidic -0.7 -0.68 -0.71 
Gemfibrozil acidic -1.31 -1.27 -1.34 
Glipizide acidic -0.69 -0.68 -0.73 
Griseofulvin neutral 0.04 0.03 0.12 
Hydrochlorothiazide weak acid -0.18 -0.17 -0.13 
Hydrocortisone neutral 0.1 0.09 0.12 
Imipramine basic 0.66 0.6 1.16 
Indomethacin acidic -0.72 -0.69 -0.96 
Isradipine neutral 0.08 0.08 0.13 
Ketoconazole weak base 0.12 0.1 0.32 
Ketoprofen acidic -0.98 -0.96 -1.01 
Labetalol amphoteric 0.38 0.34 0.71 
Lignocaine basic 0.14 0.16 0.4 
Methylprednisolone neutral 0.12 0.11 0.16 
Metronidazole weak base -0.24 -0.25 -0.25 
Minoxidil weak base -0.11 -0.1 -0.04 
Nabumetone neutral -0.09 -0.09 0.03 
Nadolol basic -0.34 -0.35 -0.33 
Nicardipine weak base 0.32 0.32 0.47 
Nifedipine neutral -0.07 -0.07 -0.04 
Nitrendipine neutral 0.08 0.08 0.16 
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Papaverine weak base -0.13 -0.13 0 
Pentoxifylline neutral -0.07 -0.07 -0.1 
Perphenazine basic 0.66 0.61 1.35 
Phenytoin weak acid -0.02 -0.02 0.03 
Pindolol basic 0.14 0.13 0.85 
Prazosin weak base -0.11 -0.13 -0.05 
Prednisolone neutral 0.12 0.12 0.14 
Prednisone neutral 0.03 0.03 0.05 
Primidone neutral -0.13 -0.13 -0.15 
Probenecid acidic -0.66 -0.64 -0.75 
Procainamide basic -0.13 -0.12 0.02 
Propanolol basic 0.64 0.59 1.29 
Propylthiouracil weak acid -0.31 -0.31 -0.34 
Proxyphylline neutral -0.75 -0.74 -0.85 
Sulfachlorpyridazine acidic -0.71 -0.7 -0.76 
Sulfameter acidic -0.57 -0.57 -0.61 
Sulfamethoxypyridazine weak acid -0.57 -0.56 -0.59 
Sulfinpyrazone acidic -0.64 -0.62 -0.65 
Sulfisoxazole acidic -0.68 -0.67 -0.72 
Sulphadimidine amphoteric -0.41 -0.41 0.22 
Sulpiride basic -0.11 -0.1 0.12 
Tamoxifen basic 0.94 0.89 1.48 
Theobromine weak acid -0.24 -0.25 -0.25 
Tolfenamic Acid acidic -0.54 -0.49 -0.76 
Trazodone weak base -0.09 -0.1 0.01 
Trimethoprim weak base -0.05 -0.06 -0.06 
Warfarin acidic -0.69 -0.68 -0.78 
 
Figure 6. The plot of the estimated log Vdss values using the CHI (IAM) values obtained on the IAM.PC.DD2 
column P20511-014-3 and from the reference [13]. The green line is the line of unity. 
Figure 7 shows the plot of the estimated log Vdss values using the CHI (IAM) values obtained on the 
IAM.PD.DD2 column P20511-014-3 and those obtained from the reference but without the 4 strong basic 
compounds (procainamide, sulpiride, zolmitriptan and pindolol). It can be seen that the agreement is 
slightly improved with an R2 value of 0.96, however, the slope is still less than one, while the intercept is 
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close to zero. This means that the rank order of the volume of distribution data would be the same when 
using the new batches of IAM.PC.DD2 columns as it was when using the old batches of IAM columns. 
However, absolute values may be slightly different for the neutral, acidic and basic compounds and greater 
discrepancies can be expected for some strong basic compounds which are similar to those left out from 
the plot. 
 
Figure 7. The plot of the estimated log Vdss values using the CHI (IAM) values obtained on column P20511-014-
3 and from the reference values [12] without the four strong basic compounds. The green line is the line of 
unity. 
It was important to investigate how the estimated volume of distribution using the CHI (IAM) data from 
the new batches of the IAM.PC.DD2 columns correlated with the actual clinical volume of distribution data. 
Figures 8 and 9 show the correlation of the estimated log Vdss values using the same coefficients as in 
equation 4 with the clinical log Vdss values. Figure 9 shows that the CHI (IAM) values obtained on the new 
batches of IAM.PC.DD2 column can be used to estimate the human clinical volume of distribution data by 
using equation 4. There is better agreement with the clinical data when using the log Vdss obtained on the 
new batch of the IAM.PC.DD2 column. However, the absolute values may be slightly different and a 
correction factor (slope 0.62) will be required. In a drug discovery setting for ranking and differentiating 
compounds using an estimated log Vdss, these values can be used with confidence. However, it is important 
to acknowledge that certain strong basic compounds may appear to have a lower volume of distribution 
than expected.  
It was also important to investigate how the CHI (IAM) and log K (IAM) values perform in other in vivo 
distribution models. 
Estimating brain tissue binding using the old and new batches of IAM.PC.DD2 columns 
The brain tissue binding can be estimated from the sum of the albumin and the phospholipid binding as 
described by equation 8. The model was built on 135 drug discovery compounds from several neuroscience 
projects using rat brain tissue binding data obtained by equilibrium dialysis and measured HSA and IAM 
binding data as described in reference [12].  
log k (BTB)=1.29 (±0.10) log k (IAM) + 1.03(±0.10) log k (HSA) - 0.237 (8) 
n=135   r2=0.76    s=0.35   F=212 
where n is the number of compounds, r2 is the correlation coefficient, s is the standard error of the 
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estimate and F is the Fisher-test value. 
 
Figure 8. The plot of the estimated and the measured clinical volume of distribution data using the old 
batches of IAM columns (reference [13] reference log Vdss) using equation 4. 
 
Figure 9. The plot of the estimated and measured clinical volumes of distribution using the new batch 
R20511-014-3 IAM.PC.DD2 column versus the reference log Vdss [13]. 
Figure 10 shows the comparison of the estimated brain tissue binding (%BTB) when the old (reference 
[13]) and the new column P20511-014-3 IAM.PC.DD2 data was used in the model.  
The agreement is very good with an R2 value of 0.95, the slope is close to 1 and the intercept is close to 
zero using the CHI (IAM) values obtained on P20511-014-3 from the latest batch of IAM.PC.DD2 columns. 
However, the four basic compounds that showed significantly lower CHI (IAM) values are significant 
outliers resulting in these compounds being estimated to have lower brain tissue binding than their actual 
brain tissue binding. 
Estimating the unbound volume of distribution using the old and new batches of IAM.PC.DD2 columns  
The agreement between the estimated unbound volume of distribution data using the reference [13] 
CHI (IAM) values and the CHI IAM values obtained on column R25011-014-3 are shown in Figure 11.  
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Figure 10. The plot of the estimated brain tissue binding (%BTB) obtained using the IAM data obtained from 
the reference [13] and that obtained using IAM.PC.DD2 column P20511-014-3 
 
Figure 11. A plot of the estimated unbound volume of distribution using the IAM data from the reference 
(reference [12]) and on the IAM.PC.DD2 R20511-014-3 column 
It can be seen that the estimated unbound volume of distribution using the CHI (IAM) values obtained 
on column R20511-014-3 shows good agreement with the logVdu from the reference CHI (IAM) values. It 
can be observed from the plot that basic compounds tend to show a lower unbound volume of distribution 
using the CHI (IAM) values obtained on the new column R20511-014-3. 
Estimating drug efficiency using the old and new batches of IAM.PC.DD2 columns 
Figure 12 shows the comparison of the estimated drug efficiency values using the old and a new batch 
(R20511-014-3) of IAM.PC.DD2 column.  
There is good agreement between the drug efficiency values obtained on the new batch of the IAM 
column and the literature data. However, the basic compounds showed greater drug efficiency than 
expected when using the new batch (R20511-014-3) of IAM.PC.DD2 column. 




Figure 12. The plot of the drug efficiency values for the investigated drugs using the IAM data obtained from 
the reference (reference [12]) and by R20511-014-3 column 
In conclusion, some differences between the old and the latest batches of IAM.PC.DD2 columns were 
observed when estimating the in vivo distribution of compounds. The discrepancies are more significant 
when the models are based on the differences between the measured IAM and HSA binding (volume of 
distribution). When the models are based on the sum of the two types of binding, the correlations 
between the estimated values (brain tissue binding, the unbound volume of distribution and drug 
efficiency) are much stronger. However, systematic differences could be observed for basic compounds in 
the estimated drug efficiency values. Polar basic (log P less than 2) compounds with over 6 rotatable bonds 
were estimated to have greater dug efficiency values than previously estimated using the old batches of 
IAM.PC.DD2 columns. These discrepancies are due to the weaker interaction of the new batches of 
IAM.PC.DD2 stationary phases with positively charged basic compounds. This could be the result of better 
endcapping procedures to block the free silanol groups and it could also be due to the higher purity of the 
silica providing less overall negatively charged silanols. 
Based on these observations it was decided to investigate the potential benefit of developing new 
models using the data obtained on the new silica based IAM stationary phase and to compare the new 
models with the existing model equation (equation 4). 
Developing new distribution models using the new batches of IAM.PC.DD2 columns 
The correlations between the old and the new batches of IAM retention data have been investigated. It 
was found that the reference CHI (IAM) data can be estimated using the CHI (IAM) data obtained on the 
new batches (P20511-014-3 and R20511-014-3) of IAM.PC.DD2 columns when the retention difference on 
C-18 columns obtained at pH 10.6 and pH 2.6 are included in the equation (equation (9)). This second 
variable significantly increased the explained variance of the reference CHI (IAM). 
Reference CHI (IAM) = 1.06(±0.03) CHI (IAM) (R-20511-01403) + 0.008(±0.01)ΔCHI (pH10.5 - pH2.6) – 1.06 
(±0.73)  (9) 
n= 67   r2=0.97 s=2.7       F=1100 
The correlation was slightly improved (from 0.92 to 0.97) between the reference CHI (IAM) values and 
the CHI (IAM) values obtained on the new batch of IAM.PC.DD2 columns. However, in order to be able to 
use equation 9, the CHI measurements on C-18 columns should be carried out at high and low pH. This 
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requires two additional measurements for each compound. When resources are limited, the calculated 
molecular descriptor can be used. The following parameters have been calculated for the investigated drug 
molecules: log P, molecular weight, number of H-bond donor and acceptor groups, total polar surface area, 
flexibility and the number of rotatable bonds (NRB). It was found that the only significant variables among 
the calculated parameters that improved the correlation between the CHI (IAM) values obtained using the 
new and old batches of IAM.PC.DD2 columns were clogP and the total polar surface area (TPSA) as shown 
in equation 10.  However, the correlation coefficient improved only slightly from 0.92 to 0.96. 
Reference CHI (IAM)=1.38(±0.07) CHI (IAM)(R20511 – 014 -3) – 2.42(±0.57) clogP -0.03(±0.01) TPSA - 1.28
 (10) 
n=68   r
2
=0.96  s=3.3   F=530 
The other option was to build a new model for the estimation of the volume of distribution using the 
new batches of IAM.PC.DD2 columns and the clinical volume of distribution data. 
The new equation for modelling clinical steady-state volume of distribution data is shown in equation 
11. The mathematical-statistical parameters are very similar to the original equation (Equation 4); 
however, the coefficients of the IAM and HSA binding data are very different. 
log Vdss clinical =0.54(±0.04) log K (IAM)(R20511-01403) - 0.24(±0.02) log K (HSA) -0.7 (11) 
n=72    r2=0.78   s=0.30 
The plot of the estimated and measured clinical steady-state volume of distribution data are shown in 
Figure 13. When comparing the coefficients of equation 4 (the published Vdss model equation) and 
equation 10, it can be seen that the coefficients for the HSA binding do not differ significantly (0.24 and 
0.22 with an error of 0.02). However, the coefficients of log K (IAM) are different at the 95 % confidence 
interval and agree only within a 90 % confidence interval: 0.54 ± 0.04 and 0.44 ± 0.02. 
 
Figure 13. The plot of the calculated log Vdss values using the new model with the CHI (IAM) values obtained 
on column (R20511-014-3) as a function of the clinical log Vdss values. 
Conclusions 
The use of a new silica support provided a slightly different selectivity for the new IAM.PC.DD2 columns 
regardless of the bonding procedure used. Therefore, new CHI (IAM) values have been proposed for the 
system suitability test compounds. New IAM.PC.DD2 columns should be evaluated using the new CHI (IAM) 
values (Table 4.). The reproducibility of the new batches of IAM.PC.DD2 columns are very good and are 
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within 2 CHI (IAM) units. The effect of the selectivity change has been investigated on previously developed 
in vivo models for drug distribution that are based on CHI (IAM) values. A set of 72 marketed drugs with 
clinical distribution data (volume of distribution, unbound volume of distribution and drug efficiency) have 
been analyzed on the new batches of IAM columns. The CHI (IAM) values were compared with the values 
obtained from the previous batches of IAM columns and it was observed that small polar basic compounds 
showed significantly shorter retention times on the new IAM.PC.DD2 columns. The correlation coefficient 
improved significantly when the data from these compounds are removed from the analysis. The possible 
reason for these discrepancies may be due to the better endcapping procedure on the new IAM columns 
which is blocking the silanol effects that increase retention of basic compounds. It is also likely that the 
newer “Type B” silica is higher purity silica with a more inert surface and creates fewer negatively charged 
silanols decreasing the amount of non-specific binding.  It was found that using the new CHI (IAM) data in 
the previously published model equations, a good correlation was obtained with the original values. 
However, the absolute values were different but the rank order for the in vivo distribution values remain 
the same using the old and the new columns. New models have also been developed for estimating the 
clinical volume of distribution of compounds using the data from the new IAM columns. The mathematical 
statistical characteristics of the new models are similar, but the coefficients of the CHI (IAM) and log K 
(HSA) parameters are slightly different. Since the correlation between the estimated and clinical volume of 
distribution data was the same or slightly better with the data obtained from the new batches of IAM 
columns, it is expected that the in vivo estimates can be as accurate with the data obtained from the new 
batches of IAM columns as with the older batches of IAM columns. The newly derived equation (eqation 
11) for the estimation of the volume of distribution is suggested when someone begins to use biomimetic 
chromatographic measurements with the new columns. However, reference can still be made to the 
existing data previously published using the older columns. 
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